Recipharm Appoints New General Manager
News Apr 30, 2015
Recipharm has announced that Giorgio Bruno has been appointed General Manager of Recipharm Italia S.p.A. In this role, he will serve as CEO for all of Recipharm’s Italian operating companies which employ some 257 people at three sites and have revenues of €57m.
Dr Bruno has long established senior management experience from within the pharmaceutical industry, especially in the area of manufacturing. He has worked in both Italian and multinational pharmaceutical companies covering a wide range of disciplines.
In particular he has had responsibility for quality and manufacturing at such companies including Parke Davis, AstraZeneca and Corden Pharma. Dr Bruno also has strong industry knowledge and has held a number of positions within Italian based industry associations. He holds a Ph. D. in Pharmaceutical Chemistry and Technology from the University of Milan.
“Commenting on the appointment, Thomas Eldered, CEO of Recipharm remarked: “I am very pleased to welcome Dr Bruno to the Recipharm team. We are very fortunate to have been able to attract such a competent and highly experienced manager to this important position and I look forward to him bringing his expertise to bear across our Italian operations for which he is now responsible.”
Methane Hydrate Formation Studied Using Novel MicroreactorNews
Researchers at the NYU Tandon School of Engineering are using a novel means of studying how methane and water form methane hydrate that allows them to examine discrete steps in the process faster and more efficiently.READ MORE
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Vapourtec Collaboration with NPM Drives New Flow TechnologyNews
Flow chemistry engineering specialists Vapourtec (UK) have been engaged in a successful collaboration with New Path Molecular Research Ltd (NPM), focusing on the development of new reactor technology and methods for peptide synthesis.READ MORE